SK Plasma Exports Technology Worth 110 Billion Won to Turkey: "Largest Deal Ever"

SK Plasma has achieved the largest technology export in its history through a plasma fractionation self-sufficiency project being promoted in partnership with the Turkish government.

On March 5, SK Plasma announced that it had signed a technology transfer and license agreement worth a total of 65 million euros (approximately 109.1 billion won) with Proturk on March 3. This marks the largest individual license agreement since SK Plasma was established in 2015. The contract includes an upfront payment of 10 million euros (about 16.8 billion won), with the remaining 55 million euros (about 92.3 billion won) to be received in installments over nine years.

Seungjoo Kim, CEO of SK Plasma (right), Fatma Meri?, President of the Red Crescent, and Ilyas Hashim, CEO of Kizlay Yatrim, are taking a commemorative photo after signing a technology transfer agreement. Photo by SK Plasma

원본보기 아이콘

Proturk is a joint venture (JV) established last November for the purpose of building plasma fractionation production facilities in cooperation with the Turkish Red Crescent. Under the terms of the agreement, SK Plasma will grant Proturk a license to manufacture products at the new Turkish facility to be built in the future, and will transfer technology related to research and development (R&D) and production. In addition, SK Plasma will acquire a 15% stake in Proturk, and the agreement structure allows SK Plasma to receive dividends based on business performance.

SK Plasma plans to expedite the technology transfer to its local subsidiary in Turkey and rapidly establish production infrastructure. The company intends to transfer the manufacturing, production, and quality management systems accumulated at its Andong plant in stages. Based on a technology transfer manual, SK Plasma will standardize the technology transfer procedures and systematically manage any risks that may arise during the process.

Once the production facility with an annual capacity of 600,000 liters is completed in the Chubuk area of Ankara, Turkey is expected to be able to stably supply essential medicines such as albumin and immunoglobulin, which were previously 100% dependent on imports.

Seungjoo Kim, CEO of SK Plasma, stated, "While expanding cooperation with the Turkish government to enhance access to medicines and strengthen the social safety net for Turkish citizens, we will also expand our business into regions in need of self-sufficiency solutions, contributing to resolving imbalances in medical systems between countries."

Meanwhile, SK Plasma is pursuing a global business model that involves building local plants and transferring technology to countries that require self-sufficiency in essential medicines, leveraging its expertise in establishing and operating plasma fractionation production facilities and systems in Andong, Gyeongbuk.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.